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bstract
Calcium, as the most abundant mineral in human body, is involved in many physiological and pathological processes. Here, we reviewed the
ey mechanisms of calcium homeostasis, including calcium sensing receptor regulation, intestinal calcium absorption, renal calcium reabsorption
nd bone calcium resorption. We further discussed the roles of dietary calcium and vitamin D in diseases associated with dysfunctional regulation
f calcium. However, the over-dosed consumption of calcium could increase the risks for a series of diseases, such as kidney stone, myocardial
nfarction and stroke.
 2016 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Calcium is the 5th of the most abundant elements in the earth
rust and is also the most abundant mineral in human body. The
uman body contains approximately 1 kg of calcium with more
han 99% deposit in the bone in the form of calcium phosphate
1]. Through interacting with numerous proteins distributed in
ifferent cellular compartments, calcium is involved in a large
mount of aspects of life, such as muscle contraction, enzyme
ctivation, cell differentiation, immune response, programmed
ell death and neuronal activity [1–11]. Such broad functions are
aintained by tightly controlled calcium concentration in extra-
ellular fluid and cellular compartments. The concentrations of
alcium in blood and extracellular fluid are usually maintained
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t 1–2 mmol/L, while the concentration of intracellular calcium
t resting state is maintained at 100 nmol/L or less by calcium
TPase, channels, and exchangers located in plasma membrane
nd endoplasmic reticulum (ER) membrane [2,12]. During the
ignaling process of calcium, the concentration of intracellular
alcium is increased to approximately 100 M, which triggers
alcium signaling through the activation or deactivation of an
rray of calcium-binding proteins. In addition, pathogens, such
s bacteria and viruses, can hijack calcium signaling to ben-
fit their own life cycles including invasion, replication and
roliferation [13,14].
Due to the regulation by calcium sensing receptor (CaSR)
ocated in the parathyroid gland, the concentration of extra-
ellular calcium is dedicatedly maintained by intestinal
bsorption, kidney reabsorption and bone resorption/formation.
he miscommunication of these processes is responsible for
alcium-related diseases, such as osteomalacia [15,16]. Amer-
cans at all ages, however, do not consume enough dietary
alcium compared with the recommendations by the Institute
f Medicine [17]. The deficiency of calcium could cause vari-
us diseases, such as osteoporosis. In this paper, we will review
he key factors controlling calcium homeostasis and further dis-
uss the diseases associated with the dysfunctional regulation of
alcium and vitamin D.
lsevier B.V. All rights reserved.
F. Pu et al. / Food Science and Human Wellness 5 (2016) 8–16 9
Fig. 1. Regulation of calcium homeostasis by CaSR. The decrease of blood calcium level activates CaSR in parathyroid gland, which further promotes the secretion
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cer cells are regulated by vitamin D. TRPV6 is also induced by
low calcium diets or at the time of weaning [31,32]. Transgenic
mice with TRPV6 overexpression can result in hypercalcemiaf PTH. PHT increases blood calcium level by the direct activation of calcium re
nd secretion of 1,25-dihydroxyvitamin D3 in kidney cells. 1,25-Dihydroxyvita
one calcium release. CaSR expressed in bone, kidney and intestine cells are al
.  Molecular  mechanism  of  extracellular  calcium
omeostasis
Extracellular calcium homeostasis is mainly controlled
y three physiological modes, including intestinal calcium
bsorption, renal calcium reabsorption, and bone forma-
ion/resorption [18], which is mainly regulated by CaSR through
he modulation of parathyroid hormone (PTH), calcitonin and
,25-dihydroxyvitamin D3 secretion (Fig. 1) [19–21].
.1.  Calcium  uptake  in  intestine
Intestine is the major organ responsible for calcium uptake.
n general, calcium from diets is absorbed by intestine through
wo pathways including transcellular absorption and paracel-
ular transport of calcium (Fig. 2). In duodenum of intestine,
ranscellular absorption is responsible for 80% calcium uptake
n low-calcium diets and less than 10% calcium uptake in
igh-calcium diets [22]. Certain calcium channels, intracellular
alcium-binding proteins and calcium pumps are responsible
or transcellular absorption of calcium. This process is initi-
ted by transient receptor potential vanilloid type 6 (TRPV6)
hannel, a transmembrane calcium selective channel located in
he brush border side membrane responsible for calcium entry
23,24]. After calcium enters the cell through TRPV6 channel,
alcium-buffering proteins bind to calcium and transport cal-
ium inside the cell. At last, calcium is excluded out of the cell to
lood vessels through plasma membrane ATPase 1b (PMCA1b)
ocated in the basolateral membrane [25].
TRPV6 channel belongs to the transient receptor potential
TRP) super family that contains 6 different proteins. TRPV1-
 are non-selective cation channels activated by protons, lipids,
nd the changes of temperature, pressure and osmolarity. TRPV5
nd TRPV6 are calcium selective channels involved in renal
alcium reabsorption and intestinal calcium absorption, respec-
ively [18,23,24]. TRPV6 is located in many types of cells,
F
tption in kidney and calcium release in bone. PHT also promotes the production
3 regulates the intestinal calcium absorption, kidney calcium reabsorption and
olved in the regulation of calcium homeostasis.
ncluding the cells from intestine, prostate cancer and breast can-
er [26–28]. The activation of TRPV6 in the brush border mem-
rane of intestine is the first step of calcium entry. This protein
ontains long intracellular N-terminal and C-terminal domains
nd 6 putative transmembrane domains. TRPV6 is also modified
hrough N-linked glycosylation [29]. Different from TRPV1-4,
RPV5 and TRPV6 are constitutively activated [24,30]. The
unctional TRPV5 and TRPV6 channels are tetramers. The
xpression levels of TRPV6 in intestine and many types of can-ig. 2. Intestinal calcium absorption by transcellular absorption and paracellular
ransport.
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nd soft tissue calcification, which further supports the role of
RPV6 in calcium absorption [31,33]. Additionally, TRPV6 is
egulated by multiple intracellular proteins including calmod-
lin, S100A10/Annexin 2, Nipsnap1 and Rab11a [34–37].
RPV6 also contains a few putative phosphorylation sites, sug-
esting that TRPV6 is modulated by kinases [22].
The second phase of transcellular absorption for calcium
s mediated by a calcium-buffering protein, calbindin D9k as
n intracellular calcium-binding protein. This protein has one
lassical EF-hand and one pseudo EF hand. Both EF-hands
ooperatively bind calcium with high affinity [38,39]. Unlike
arvalbumin [40,41], calbindin D9k has relatively low affinity
o Mg2+. The expression level of calbindin D9k in intestine can
e regulated by 1,25-dihydroxyvitamin D3, low dietary calcium
onditions or at the time of weaning [31,32,42].
Although the roles of TRPV6, calbindin D9k and PMCA1
n transcellular calcium absorption are well studied, the studies
ith gene knockout mice suggest that TRPV6 channel and cal-
indin D9k are not essential for the intestinal calcium uptake
nd the functions of TRPV6 and calbindin D9k in transcellu-
ar calcium absorption may be compensated by other proteins
43,44].
The third step of transcellular calcium absorption is mediated
y PMCA1b. As a common mechanism of PMCA, PMCA1b
ransports intracellular calcium to blood in an energy-dependent
eaner. Animals adapted to diets with low calcium and low
hosphorus or induced by vitamin D can increase the expres-
ion of PMCA1b in the basolateral membrane of intestinal cells
45,46]. Besides, sodium–calcium exchangers including NCX1,
re also involved in calcium extrusion in the basal lateral mem-
rane [22].
Different from transcellular absorption of calcium, paracellu-
ar transport of calcium is a non-saturable, energy-independent
athway. Paracellular transport of calcium can be observed
hroughout the intestine and is the major pathway for calcium
ptake, especially under the condition with high-calcium diets.
ompared with transcellular calcium absorption, the molecu-
ar mechanism of paracellular calcium transport is less well
tudied. However, it is clear that tight junction plays a crit-
cal role in the regulation of this event. The permeability of
ight junction is regulated by many proteins including claudin 2
nd 12 [22,31]. In addition, 1,25-dihydroxyvitamin D3 regulates
aracellular calcium transport by suppressing the expression of
laudin 3, aquaporin 8, cadherin 17, and RhoA, thus improving
he permeability of tight junction [47,48].
.2.  Calcium  reabsorption  in  kidney
Kidney is another essential organ for calcium sensing and
eabsorption. Calcium is absorbed in nephron with the high-
st absorption in proximal tubules [18]. The renal calcium
eabsorption comprises of two pathways including paracellu-
ar pathway and transepithelial pathway. Similar as transcellular
alcium absorption in intestine, transepithelial calcium reab-
orption in kidney also contains three major steps. First, calcium
s transported to the intracellular space through calcium chan-
els located in the epical membrane. TRPV5 is the major
t
i
i
aan Wellness 5 (2016) 8–16
alcium channel located in the epical plasma membrane respon-
ible for calcium transportation. TRPV5 is a calcium-selective
hannel with 75% amino acid identity to TRPV6 [18,49]. The
-terminal of TRPV5 contains six ankyrin repeats involved
n the tetramer formation and protein–protein interaction. The
-terminal of TRPV5 contains a phosphorylation site of pro-
ein kinase C. The kidney calcium reabsorption is impaired in
RPV5 knockout mice, suggesting the critical role of TRPV5 in
his process [18,50]. TRPV5 is regulated by many biomolecules,
nd can be activated by kallikrein or bradykinin receptor through
LC/DAG/PKC pathway [51]. Similar to TRPV6, TRPV5 is
egulated by annexin-2, Rab11a, calmodulin and other proteins
18,24]. Second, the intracellular calcium binds to calcium-
uffering proteins, such as calbindin D28k and calbindin D9k,
nd passively diffused to the basolateral membrane through cal-
ium gradient. Calbindin D28k contains three pairs of EF-hand
otifs with 6 calcium-binding sites. This protein dynami-
ally controls calcium reabsorption through the interaction with
RPV5 at low intracellular calcium concentration [52]. Renal
alcium reabsorption is disrupted in calbindin D28k knockout
ice with high calcium diets [18,53], while other group shows
hat the effect of calbindin D28k on calcium transport is com-
ensated by other proteins including calbindin D9k [18,54]. At
ast, calcium is transported to blood by PMCA1b and/or NCX1
ocated in the basolateral membrane.
Calcium reabsorption in kidney is modulated by PTH,
,25-dihydroxyvitamin D3 and estrogen. PTH reduces the
xpression levels of TRPV5, calbindin D28k, PMCA1b
nd NCX1 in kidney cells through PTH receptor (PTHR)-
ediated signaling pathway. PTH also stimulates the pro-
uction of 1,25-dihydroxyvitamin D3 in proximal tubules.
,25-Dihydroxyvitamin D3, produced from kidney and other
rgans, down-regulates the expression of TRPV5, NCX1 and
albindin D28k in kidney cells. The expression level of PMCA1b
n these cells, however, is not significantly affected by 1,25-
ihydroxyvitamin D3. Additionally, animal experiments also
uggest that certain estrogen can increase the expression of
enal reabsorption-related proteins, such as TRPV5, PMCA1b,
albindin D28k and NCX1 [18,55].
.3.  Bone  calcium  regulation
Besides intestinal absorption and renal reabsorption of cal-
ium, bone resorption is an important mechanism to modulate
alcium level in blood. Bone is constantly remodeled by
steoblasts and osteoclast. Osteoblasts facilitate bone forma-
ion, while osteoclasts break bone tissue and release calcium.
he development and activation of osteoclasts are mediated by
eceptor activator of NF-B (RANK) ligand (RANKL). The
xpression of RANKL is promoted by vitamin D3, PTH, PTHrP,
NF-, IL-1, IL-6, IL-11 and IL-17 and inhibited by TGF-
 [57–62]. On the other hand, the activity of RANKL is also
nhibited by osteoprotegerin (OPG), a secreted protein func-
ioning as a decoy receptor for RANKL. OPG disrupts the
nteraction between RANK and RANKL by competitively bind-
ng to RANKL, and functions as an inhibitor for the development
nd activation of osteoclasts. The expression level of OPG in
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uman bone marrow cells is inhibited by 1,25-dihydroxyvitamin
3 and PTH [63–65]. Thus, 1,25-dihydroxyvitamin D3 and PTH
odulate calcium resorption in bone by increasing RNAKL
xpression and decreasing OPG expression.
.4.  Calcium  homeostasis  by  CaSR  regulation
Calcium level in blood is mainly maintained by CaSR located
n the parathyroid gland. CaSR belongs to family C of G-
rotein coupled receptor. Other members in this family include
etabotropic glutamate receptor, GABAB receptor and taste
eceptor [66–69]. CaSR has seven transmembrane domains. The
ength of the extracellular and intracellular domain of CaSR
aries in different cell types due to alternative splicing. The N-
erminal of extracellular domain of CaSR contains more than 500
esidues. It interacts with multiple ligands, indicating that this
rotein has multiple functions in sensing micro-environmental
hanges. CaSR is usually expressed as homodimer or het-
rodimers in the plasma membrane. A cysteine rich region
ocated in the extracellular domain of CaSR is critical for the
imerization of CaSR [70,71].
The C-terminal of intracellular domain of CaSR interacts
ith many cell signaling proteins [72]. Protein kinase C reg-
lates CaSR functions by the phosphorylation of several serine
esidues in the intracellular domain. An ubiquitin ligase, dorfin,
ynamically interacts with intracellular domain of CaSR, and
egulates trafficking and degradation of CaSR [73]. Like other
-protein coupled receptors, CaSR is phosphorylated by G pro-
ein receptor kinases (GRKs) in the second or third loop [72]. The
-arrestin binds to the phosphorylated loop and blocks the inter-
ction between CaSR and G-protein. The -arrestin binding also
acilitates the receptor internalization and activates ERKs in a G
rotein-independent manner [74]. Filamin is a scaffold protein
hat interacts with CaSR and modulates CaSR signaling [75].
aSR also interacts with caveolin-1, a 22 kDa transmembrane
rotein extensively expressed in caveolea [76], and regulates
he expression and activation of inducible nitric oxide synthase
iNOS) [77]. Caveolin-1 also can be involved in trafficking
f cholesterol and sphingolipids, and serve as a scaffold pro-
ein to modulate signaling transduction. However, the functions
f intestinal chloride ion channel and exchangers regulated by
aSR are not clear yet, although CaSR is able to modulate Ca2+
nd IP3 dependent Cl− current in CaSR-overexpressed oocytes
78].
One of the major functions of CaSR is regulating systemic
a2+ homeostasis [79,80]. Ca2+ is the primary ligand of CaSR.
t least four calcium-binding sites are reported in the extracel-
ular domain of CaSR. CaSR cooperatively binds to Ca2+ when
xtracellular concentration of Ca2+ increases [81,82]. CaSR is
lso able to sense Mg2+, amino acids, pH, antibiotics and pep-
ides, and subsequently activates downstream Gi (G inhibitory)
nd Gq as well as G12/13 pathways [80]. The activation of CaSR
an inhibit cAMP production, activate ERK pathway through Gi
2+athway, activate PLC-IP3 cascades, and release Ca from ER
ia Gq pathway. It also can activate Rho and phospholipids D
y G12/13 pathway [72]. In healthy individuals, a slight change
f calcium concentration in the extracellular fluid can trigger
r
e
r
man Wellness 5 (2016) 8–16 11
he downstream signaling of CaSR in the parathyroid gland,
hich can further induce the change of PTH secretion and sub-
equently influence the cells in intestine, kidney and bone to
djust the concentration of extracellular calcium [70,83].
CaSR regulates extracellular calcium levels in several aspects
Fig. 1). First, CaSR regulates the secretion of PTH that has
irect effects on calcium reabsorption in kidney and bone remod-
ling. Second, the increase of PTH stimulates the production
nd secretion of 1,25-dihydroxyvitamin D3 in proximal tubules
s the key molecule for the regulation of the intestinal cal-
ium absorption, kidney calcium reabsorption and bone calcium
elease [83]. Third, the activation of CaSR, in some cases,
nhibits the activity of osteoclasts, which further suppresses bone
alcium release [84]. Forth, CaSR further modulates extracellu-
ar calcium level by regulating calcitonin selection in thyroidal
-cells [85,86]. Moreover, CaSR is highly expressed in the
igestive system including pancreas, stomach, small intestine
nd large intestine. In small intestine, CaSR modulates motil-
ty and development of intestine, NaCl and H2O transport,
a2+/Mg2+ absorption and nutrient absorption [87]. Further-
ore, CaSR expressed in renal tubules also can directly regulate
he filtering and reabsorption of metal ions, including calcium
70].
.  Calcium  diets,  supplements,  vitamin  D and  diseases
Food is an important source for calcium uptake. The com-
on calcium-rich foods include milk, yogurt, cheese, shrimp,
oybean, soy milk, tofu, broccoli, orange, kale and others. The
ajor forms of calcium supplements are calcium carbonate and
alcium citrate. Americans at all ages, however, do not take
nough dietary calcium compared with the recommendations
y the Institute of Medicine [17]. Sufficient calcium intake is
mportant for human health and calcium deficiency could lead
o diseases, such as osteoporosis and rickets [88,89].
Bone is a living and constantly remodeling tissue [90]. The
ld or damaged bone is resorbed by osteoclasts and the new bone
s constructed by osteoblasts [56]. Bone is primarily composed
f organic components and inorganic components. The organic
omponents are consisted mainly of type I collagen responsi-
le for bone flexibility. The inorganic components comprised
f hydroxyapatite, insoluble salts containing calcium and phos-
horus provide bone strength against compression [90]. The
oncentration of calcium in serum is usually kept in a very
imited range so as to prevent the disorder of some physiological
unctions, such as muscle contraction [91]. Bone is a mineral
eservoir for calcium and phosphorus. Over 99% of total cal-
ium in human body is stored in bone and teeth. Calcium plays
mportant roles in the formation process of new bone and main-
enance of existing bone by collaborating with other factors such
s phosphorus, vitamin D and calcium-binding proteins [92].
Dietary calcium intake is critical for the calcium homeostasis
f bone. Supplementary diets containing calcium with average
ecommended dietary allowance for children increase bone min-
ral density (BMD) and reduce the risk of fracture [93]. As
eviewed in the previous section, calcium homeostasis is well
aintained in the cells from intestine, kidney and bone. When
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erum calcium level is low, CaSR promotes the secretion of PTH
nd indirectly increases 1,25-dihydroxyvitamin D3 level. When
ietary calcium intake from intestine is low, blood calcium level
s maintained by kidney reabsorption and bone calcium release
t the expense of bone strength [94]. On the other hand, lack of
itamin D could cause serious health problems. Low vitamin D
evel limits the synthesis of 1,25-dihydroxyvitamin D3, which
urther reduces blood calcium level through the inhibition of
ntestinal calcium absorption and renal calcium absorption. The
TH level, however, increases in response to the reduced blood
alcium level. The increase of PTH promotes bone remodeling,
hile low calcium inhibits bone mineralization, correspondingly
eading to the increased osteoid [94].
Some studies have demonstrated that patients with specific
iseases or disease treatments may have skeletal abnormalities.
or example, valproate, a chronic antiepileptic therapy, may
ause low bone mass in pediatric patients and sufficient intake of
alcium can offset this harmful effect [95]. BMD is significantly
ower in patients with Parkinson’s disease than the healthy peo-
le and the lower BMD is correlated with severe progression of
he disease [96]. The loss of BMD is the early sign of osteopenia
hat can turn into osteoporosis. Osteoporosis can lead to fracture
nd other severe bone diseases. Current studies reveal that ade-
uate intake of calcium can decrease the risk of osteoporosis,
racture and diabetes in some cases [92].
The role of calcium in cancer has been explored for almost
00 years [97]. The relationship between calcium and cancer,
owever, is still controversial. A previous randomized trial has
emonstrated that the supplementation of calcium and vitamin
 for seven years has no effects on colorectal cancer [98]. High
alcium intake, however, seems to reduce the risk of breast
ancer and the increase the risk of prostate cancer [99].
reast cancer is the most common cancer in women in the
nited States and China [100]. Early diagnosis, prognosis
nd treatment of cancers through biomarkers, such as HER-2
nd gastrin-releasing peptide receptor (GRPR), are actively
tudied in animal models [101–106]. On the other hand, cancer
revention through diet interventions is a hot topic with the aim
f reducing and preventing cancer occurrence. High calcium
ntake seems to reduce the risk of some cancers, such as breast
ancer [99]. Vitamin D and calcium shows anti-breast cancer
ffects through regulating signaling pathways associated with
ell proliferation, invasion and apoptosis. Epidemiological
tudies show that the intake of dietary and supplementary
alcium and vitamin D reduces the risk of breast cancer. Addi-
ionally, the levels of serum calcium and vitamin D metabolites
re inversely correlated with breast cancer [107]. The mutations
n vitamin D receptor and calcium sensing receptor are also
dentified in breast cancer tissue, suggesting the involvement
f calcium and vitamin D signaling in breast cancer [107–109].
RPV6 can exhibit the up-regulation by 2–15 folds in breast
ancer tissue when compared with that in normal breast tissue.
he expression level of TRPV6 is reduced in breast cancer cellines in the presence of tamoxifen, an antagonist of estrogen
eceptor [110], and can be up-regulated by 1,25-vitamin D.
he overexpression of TRPV6 is also observed in the highly
nvasive area of breast cancer [111]. Therefore, further studies
Can Wellness 5 (2016) 8–16
n the relationship between dietary vitamin D/calcium and
RPV6 in breast cancer are highly desired.
Additionally, dietary calcium involves in cardiovascular dis-
ases. High calcium intake could induce fatty acids and bile to
ind to calcium, which further inhibits intestinal calcium absorp-
ion and therefore reduces cholesterol level in blood [112–114].
lood calcium also regulates blood pressure by modulating
enin-angiotensin system [113–115].
Whether calcium supplements can be beneficial or harm-
ul to the health of people is still controversial. Although the
ffects of calcium supplements or casual calcium uptake on
ealth outcomes have been systematically reviewed [99], the
isks of calcium supplements for cardiovascular diseases have
ot been completely understood [116]. High calcium intake can
lightly improve BMD in children and pregnant woman. There
s no consistent conclusion between calcium intake and cardio-
ascular diseases, except blood pressure. Similarly, although
ome studies show that people with high calcium intake has
ower chance of overweight and obesity [117], the relation-
hip between calcium and obesity is still controversial. Calcium
upplementation in diets can contribute to the reduced rate of
one loss and fracture incidence in elders; however, it can
lso increase the risks of acute gastrointestinal events, kidney
tone, and cardiovascular diseases such as myocardial infarc-
ion and stroke [118,119]. Based on the meta-analysis, only
0% fracture incidence is reduced due to the calcium supple-
entation, but the incidences of myocardial infarction and
troke are increased up to 27%–31% and 12%–20%, respec-
ively [119]. Moreover, high calcium intake for men also has
he potential for the risk of advanced and fatal prostate cancer
17,120,121].
.  Conclusion
Calcium is the most abundant mineral in human body with
9% deposit in bone. The intestinal absorption, kidney reab-
orption and bone resorption are three major events for calcium
omeostasis regulated by CaSR through a series of compli-
ated mechanisms. Any miscommunication of these processes
an lead to diseases associated with dysfunctional regulation of
alcium. In addition, calcium in diets and supplements along
ith vitamin D play critical roles in calcium homeostasis. Low
alcium intake or low vitamin D level can also result in bone dis-
ases. High calcium intake can reduce the risk of breast cancer
nd contribute to the reduced rate of bone loss and fracture inci-
ence in elders. On the other hand, although high calcium intake
an reduce the risk of many diseases, it also can increase the risks
f acute gastrointestinal events, kidney stone, and cardiovascu-
ar diseases such as myocardial infarction and stroke. Therefore,
he consumption and supplementation of calcium should abide
y the health status of individuals.onﬂict  of  interest
The authors declare no conflict of interest.
d Hum
A
S
P
I
t
RF. Pu et al. / Food Science an
cknowledgements
This work is financially supported by the National Natural
cience Foundation of China (No. 31571228), Chutian Scholar
rogram from Education Department of Hubei Province and
nnovative Start-up Foundation from Wuhan Sports University
o NC.
eferences
[1] Y. Zhou, S. Xue, J.J. Yang, Calciomics: integrative studies of
Ca2+-binding proteins and their interactomes in biological systems, Met-
allomics 5 (1) (2013) 29–42.
[2] D.E. Clapham, Calcium signaling, Cell. 131(6) 1047-1058.
[3] L.R. Zhong, S. Estes, L. Artinian, V. Rehder, Nitric oxide regulates neu-
ronal activity via calcium-activated potassium channels, PLOS ONE 8
(11) (2013) e78727.
[4] Y. Chen, S.G. Naik, J. Krzystek, S. Shin, W.H. Nelson, S. Xue, J.J. Yang,
V.L. Davidson, A. Liu, Role of calcium in metalloenzymes: effects of
calcium removal on the axial ligation geometry and magnetic proper-
ties of the catalytic diheme center in MauG, Biochemistry 51 (8) (2012)
1586–1597.
[5] C. Yanyi, X. Shenghui, Z. Yubin, Y.J. Jie, Calciomics: prediction and
analysis of EF-hand calcium binding proteins by protein engineering,
Sci. China Chem. 53 (1) (2010) 52–60.
[6] G. Fu, A.A. Chumanevich, J. Agniswamy, B. Fang, R.W. Harrison, I.T.
Weber, Structural basis for executioner caspase recognition of P5 position
in substrates, Apoptosis 13 (11) (2008) 1291–1302.
[7] K. Zhao, X. Wang, H.C. Wong, R. Wohlhueter, M.P. Kirberger, G. Chen,
J.J. Yang, Predicting Ca2+-binding sites using refined carbon clusters,
Proteins 80 (12) (2012) 2666–2679.
[8] H. Zhang, L. Wang, R.W. Compans, B.Z. Wang, Universal influenza
vaccines, a dream to be realized soon, Viruses 6 (5) (2014) 1974–1991.
[9] X. Wang, K. Zhao, M. Kirberger, H. Wong, G. Chen, J.J. Yang, Analysis
and prediction of calcium-binding pockets from apo-protein structures
exhibiting calcium-induced localized conformational changes, Protein
Sci. 19 (6) (2010) 1180–1190.
[10] H. Zhang, M.E. El Zowalaty, DNA-based influenza vaccines as immuno-
prophylactic agents toward universality, Future Microbiol. 11 (2016)
153–164.
[11] X. Wang, M. Kirberger, F. Qiu, G. Chen, J.J. Yang, Towards predicting
Ca2+-binding sites with different coordination numbers in proteins with
atomic resolution, Proteins 75 (4) (2009) 787–798.
[12] Y. Chen, S. Xue, J. Zou, J.R. Lopez, J.J. Yang, C.F. Perez, Myoplasmic
resting Ca2+ regulation by ryanodine receptors is under the control of a
novel Ca2+-binding region of the receptor, Biochem. J. 460 (2) (2014)
261–271.
[13] Y. Zhou, S. Xue, Y. Chen, J.J. Yang, Probing Ca2+-binding capability
of viral proteins with the EF-hand motif by grafting approach, Methods
Mol. Biol. 963 (2013) 37–53.
[14] Y. Zhou, S. Xue, J. Yang, Calcium and viruses, in: R. Kretsinger, V. Uver-
sky, E. Permyakov (Eds.), Encyclopedia of Metalloproteins, Springer,
New York, 2013, pp. 415–424.
[15] J. Adachi, W. Bensen, F. Bianchi, A. Cividino, S. Pillersdorf, R. Sebaldt,
P. Tugwell, M. Gordon, M. Steele, C. Webber, Vitamin D and calcium in
the prevention of corticosteroid induced osteoporosis: a 3 year followup,
J. Rheumatol. 23 (6) (1996) 995–1000.
[16] P.J. Marie, J.M. Pettifor, F.P. Ross, F.H. Glorieux, Histological osteoma-
lacia due to dietary calcium deficiency in children, N. Engl. J. Med. 307
(10) (1982) 584–588.
[17] D.A. Straub, Calcium supplementation in clinical practice: a review
of forms, doses, and indications, Nutr. Clin. Pract. 22 (3) (2007)
286–296.
[18] S. Boros, R.J. Bindels, J.G. Hoenderop, Active Ca(2+) reabsorption in
the connecting tubule, Pflugers Arch. 458 (1) (2009) 99–109.an Wellness 5 (2016) 8–16 13
[19] E.M. Brown, M. Pollak, S.C. Hebert, The extracellular calcium-sensing
receptor: its role in health and disease, Annu. Rev. Med. 49 (1) (1998)
15–29.
[20] C. Zhang, C.L. Miller, E.M. Brown, J.J. Yang, The calcium sensing recep-
tor: from calcium sensing to signaling, Sci. China Life Sci. 58 (1) (2015)
14–27.
[21] J. Tfelt-Hansen, E.M. Brown, The calcium-sensing receptor in normal
physiology and pathophysiology: a review, Crit. Rev. Clin. Lab. Sci. 42
(1) (2005) 35–70.
[22] R.C. Khanal, I. Nemere, Regulation of intestinal calcium transport, Annu.
Rev. Nutr. 28 (2008) 179–196.
[23] S.F. van de Graaf, I. Boullart, J.G. Hoenderop, R.J. Bindels, Regulation
of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1, 25-dihydroxy
Vitamin D 3 and dietary Ca2+, J. Steroid Biochem. Mol. Biol. 89 (2004)
303–308.
[24] S.F. van de Graaf, J.G. Hoenderop, R.J. Bindels, Regulation of TRPV5
and TRPV6 by associated proteins, Am. J. Physiol.-Renal Physiol. 290
(6) (2006) F1295–F1302.
[25] S. Christakos, P. Dhawan, A. Porta, L.J. Mady, T. Seth, Vitamin D and
intestinal calcium absorption, Mol. Cell Endocrinol. 347 (1–2) (2011)
25–29.
[26] A.A. Peters, P.T. Simpson, J.J. Bassett, J.M. Lee, L. Da Silva, L.E. Reid, S.
Song, M.-O. Parat, S.R. Lakhani, P.A. Kenny, Calcium channel TRPV6 as
a potential therapeutic target in estrogen receptor–negative breast cancer,
Mol. Cancer Therap. 11 (10) (2012) 2158–2168.
[27] T. Fixemer, U. Wissenbach, V. Flockerzi, H. Bonkhoff, Expression of
the Ca2+-selective cation channel TRPV6 in human prostate cancer: a
novel prognostic marker for tumor progression, Oncogene 22 (49) (2003)
7858–7861.
[28] L. Lieben, B. Benn, D. Ajibade, I. Stockmans, K. Moermans, M. Hedi-
ger, J. Peng, S. Christakos, R. Bouillon, G. Carmeliet, Trpv6 mediates
intestinal calcium absorption during calcium restriction and contributes
to bone homeostasis, Bone 47 (2) (2010) 301–308.
[29] E. den Dekker, J.G. Hoenderop, B. Nilius, R.J. Bindels, The epithelial cal-
cium channels, TRPV5 & TRPV6: from identification towards regulation,
Cell Calcium 33 (5) (2003) 497–507.
[30] R. Vennekens, J.G. Hoenderop, J. Prenen, M. Stuiver, P.H. Willems, G.
Droogmans, B. Nilius, R.J. Bindels, Permeation and gating properties
of the novel epithelial Ca(2+) channel, J. Biol. Chem. 275 (6) (2000)
3963–3969.
[31] S. Christakos, Mechanism of action of 1,25-dihydroxyvitamin D3 on
intestinal calcium absorption, Rev. Endocr. Metab. Disord. 13 (1) (2012)
39–44.
[32] Y. Song, X. Peng, A. Porta, H. Takanaga, J.B. Peng, M.A. Hediger, J.C.
Fleet, S. Christakos, Calcium transporter 1 and epithelial calcium channel
messenger ribonucleic acid are differentially regulated by 1,25 dihydrox-
yvitamin D3 in the intestine and kidney of mice, Endocrinology 144 (9)
(2003) 3885–3894.
[33] M. Cui, Q. Li, R. Johnson, J.C. Fleet, Villin promoter-mediated transgenic
expression of transient receptor potential cation channel, subfamily V,
member 6 (TRPV6) increases intestinal calcium absorption in wild-type
and vitamin D receptor knockout mice, J. Bone Mineral Res. 27 (10)
(2012) 2097–2107.
[34] T.T. Lambers, A.F. Weidema, B. Nilius, J.G. Hoenderop, R.J. Bindels,
Regulation of the mouse epithelial Ca2+ channel TRPV6 by the Ca2+-
sensor calmodulin, J. Biol. Chem. 279 (28) (2004) 28855–28861.
[35] S.F. van de Graaf, J.G. Hoenderop, D. Gkika, D. Lamers, J. Prenen,
U. Rescher, V. Gerke, O. Staub, B. Nilius, R.J. Bindels, Functional
expression of the epithelial Ca2+ channels (TRPV5 and TRPV6) requires
association of the S100A10–annexin 2 complex, EMBO J. 22 (7) (2003)
1478–1487.
[36] J.P.H. Schoeber, C.N. Topala, K.P. Lee, T.T. Lambers, G. Ricard,
A.W.C.M. van der Kemp, M.A. Huynen, J.G.J. Hoenderop, R.J.M.
Bindels, Identification of Nipsnap1 as a novel auxiliary protein inhib-
iting TRPV6 activity, Pflügers Arch. – Eur. J. Physiol. 457 (1) (2008)
91–101.
[37] S.F. van de Graaf, Q. Chang, A.R. Mensenkamp, J.G. Hoenderop,
R.J. Bindels, Direct interaction with Rab11a targets the epithelial Ca2+
1 d Hum4 F. Pu et al. / Food Science an
channels TRPV5 and TRPV6 to the plasma membrane, Mol. Cell. Biol.
26 (1) (2006) 303–312.
[38] B.B. Kragelund, M. Jönsson, G. Bifulco, W.J. Chazin, H. Nilsson,
B.E. Finn, S. Linse, Hydrophobic core substitutions in calbindin D9k:
effects on Ca2+ binding and dissociation, Biochemistry 37 (25) (1998)
8926–8937.
[39] N. Chen, Y. Ye, J. Zou, S. Li, S. Wang, A. Martin, R. Wohlhueter, J.J. Yang,
Fluorescence complementation via EF-hand interactions, J. Biotechnol.
142 (3–4) (2009) 205–213.
[40] S. Xue, H. Yang, J. Qiao, F. Pu, J. Jiang, K. Hubbard, K. Hekmatyar,
J. Langley, M. Salarian, R.C. Long, Protein MRI contrast agent with
unprecedented metal selectivity and sensitivity for liver cancer imaging,
Proc. Natl. Acad. Sci. U. S. A. 112 (21) (2015) 6607–6612.
[41] M.T. Henzl, J.D. Larson, S. Agah, Estimation of parvalbumin Ca2+- and
Mg2+-binding constants by global least-squares analysis of isothermal
titration calorimetry data, Anal. Biochem. 319 (2) (2003) 216–233.
[42] J.B. Peng, E.M. Brown, M.A. Hediger, Apical entry channels in calcium-
transporting epithelia, News Physiol. Sci. 18 (2003) 158–163.
[43] G.D. Kutuzova, S. Akhter, S. Christakos, J. Vanhooke, C. Kimmel-Jehan,
H.F. DeLuca, Calbindin D9k knockout mice are indistinguishable from
wild-type mice in phenotype and serum calcium level, Proc. Natl. Acad.
Sci. U. S. A. 103 (33) (2006) 12377–12381.
[44] G.D. Kutuzova, F. Sundersingh, J. Vaughan, B.P. Tadi, S.E. Ansay,
S. Christakos, H.F. DeLuca, TRPV6 is not required for 1, 25-
dihydroxyvitamin D3-induced intestinal calcium absorption in vivo, Proc.
Natl. Acad. Sci. U. S. A. 105 (50) (2008) 19655–19659.
[45] Q. Cai, J.S. Chandler, R.H. Wasserman, R. Kumar, J.T. Penniston, Vitamin
D and adaptation to dietary calcium and phosphate deficiencies increase
intestinal plasma membrane calcium pump gene expression, Proc. Natl.
Acad. Sci. U. S. A. 90 (4) (1993) 1345–1349.
[46] J.A. Johnson, R. Kumar, Renal and intestinal calcium transport: roles of
vitamin D and vitamin D-dependent calcium binding proteins, Semin.
Nephrol. 14 (2) (1994) 119–128.
[47] G.D. Kutuzova, H.F. Deluca, Gene expression profiles in rat intestine
identify pathways for 1,25-dihydroxyvitamin D(3) stimulated calcium
absorption and clarify its immunomodulatory properties, Arch. Biochem.
Biophys. 432 (2) (2004) 152–166.
[48] S. Christakos, Recent advances in our understanding of 1,25-
dihydroxyvitamin D(3) regulation of intestinal calcium absorption, Arch.
Biochem. Biophys. 523 (1) (2012) 73–76.
[49] J.B. Peng, X.Z. Chen, U.V. Berger, P.M. Vassilev, H. Tsukaguchi, E.M.
Brown, M.A. Hediger, Molecular cloning and characterization of a
channel-like transporter mediating intestinal calcium absorption, J. Biol.
Chem. 274 (32) (1999) 22739–22746.
[50] J.G. Hoenderop, J.P. van Leeuwen, B.C. van der Eerden, F.F. Kersten,
A.W. van der Kemp, A.M. Merillat, J.H. Waarsing, B.C. Rossier, V. Val-
lon, E. Hummler, R.J. Bindels, Renal Ca2+ wasting, hyperabsorption, and
reduced bone thickness in mice lacking TRPV5, J. Clin. Invest. 112 (12)
(2003) 1906–1914.
[51] D. Gkika, C.N. Topala, Q. Chang, N. Picard, S. Thebault, P. Houillier, J.G.
Hoenderop, R.J. Bindels, Tissue kallikrein stimulates Ca(2+) reabsorption
via PKC-dependent plasma membrane accumulation of TRPV5, EMBO
J. 25 (20) (2006) 4707–4716.
[52] T.T. Lambers, F. Mahieu, E. Oancea, L. Hoofd, F. de Lange, A.R.
Mensenkamp, T. Voets, B. Nilius, D.E. Clapham, J.G. Hoenderop,
Calbindin-D28K dynamically controls TRPV5-mediated Ca2+ transport,
EMBO J. 25 (13) (2006) 2978–2988.
[53] K. Sooy, T. Schermerhorn, M. Noda, M. Surana, W.B. Rhoten, M. Meyer,
N. Fleischer, G.W. Sharp, S. Christakos, Calbindin-D(28k) controls
[Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k)
knockout mice and beta cell lines, J. Biol. Chem. 274 (48) (1999)
34343–34349.
[54] D. Gkika, Y.J. Hsu, A.W. van der Kemp, S. Christakos, R.J. Bindels,
J.G. Hoenderop, Critical role of the epithelial Ca2+ channel TRPV5 in
active Ca2+ reabsorption as revealed by TRPV5/calbindin-D28K knock-
out mice, J. Am. Soc. Nephrol. 17 (11) (2006) 3020–3027.
[55] M. Van Abel, J.G. Hoenderop, O. Dardenne, R. St Arnaud, C.H.
Van Os, H.J. Van Leeuwen, R.J. Bindels, 1,25-dihydroxyvitaminan Wellness 5 (2016) 8–16
D(3)-independent stimulatory effect of estrogen on the expression of
ECaC1 in the kidney, J. Am. Soc. Nephrol. 13 (8) (2002) 2102–2109.
[56] S.C. Manolagas, R.L. Jilka, Bone marrow, cytokines, and bone remodel-
ing. Emerging insights into the pathophysiology of osteoporosis, N. Engl.
J. Med. 332 (5) (1995) 305–311.
[57] S. Kitazawa, K. Kajimoto, T. Kondo, R. Kitazawa, Vitamin D3 sup-
ports osteoclastogenesis via functional vitamin D response element
of human RANKL gene promoter, J. Cell. Biochem. 89 (4) (2003)
771–777.
[58] Y.L. Ma, R.L. Cain, D.L. Halladay, X. Yang, Q. Zeng, R.R. Miles, S. Chan-
drasekhar, T.J. Martin, J.E. Onyia, Catabolic effects of continuous human
PTH (1-38) in vivo is associated with sustained stimulation of RANKL
and inhibition of osteoprotegerin and gene-associated bone formation,
Endocrinology 142 (9) (2001) 4047–4054.
[59] K.T. Steeve, P. Marc, T. Sandrine, H. Dominique, F. Yannick, IL-6,
RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysi-
ology, Cytokine Growth Factor Rev. 15 (1) (2004) 49–60.
[60] K.K. Mak, Y. Bi, C. Wan, P.-T. Chuang, T. Clemens, M. Young, Y. Yang,
Hedgehog signaling in mature osteoblasts regulates bone formation and
resorption by controlling PTHrP and RANKL expression, Dev. Cell. 14
(5) (2008) 674–688.
[61] E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen, P. Schwarzen-
berger, C.J.J. Coenen-de Roo, J.K. Kolls, L.A.B. Joosten, W.B. van den
Berg, IL-17 promotes bone erosion in murine collagen-induced arthritis
through loss of the receptor activator of NF-B ligand/osteoprotegerin
balance, J. Immunol. 170 (5) (2003) 2655–2662.
[62] M. Karst, G. Gorny, R.J.S. Galvin, M.J. Oursler, Roles of stromal cell
RANKL, OPG, and M-CSF expression in biphasic TGF- regulation of
osteoclast differentiation, J. Cell. Physiol. 200 (1) (2004) 99–106.
[63] L.C. Hofbauer, M. Schoppet, Clinical implications of the osteoprote-
gerin/RANKL/RANK system for bone and vascular diseases, JAMA 292
(4) (2004) 490–495.
[64] L.E. Theill, W.J. Boyle, J.M. Penninger, RANK-L and RANK: T cells,
bone loss, and mammalian evolution, Annu. Rev. Immunol. 20 (1) (2002)
795–823.
[65] W.J. Boyle, W.S. Simonet, D.L. Lacey, Osteoclast differentiation and
activation, Nature 423 (6937) (2003) 337–342.
[66] C. Zhang, Y. Huang, Y. Jiang, N. Mulpuri, L. Wei, D. Hamelberg,
E.M. Brown, J.J. Yang, Identification of an L-phenylalanine binding site
enhancing the cooperative responses of the calcium-sensing receptor to
calcium, J. Biol. Chem. 289 (8) (2014) 5296–5309.
[67] Y. Jiang, Y. Huang, H.C. Wong, Y. Zhou, X. Wang, J. Yang, R.A.
Hall, E.M. Brown, J.J. Yang, Elucidation of a novel extracellular
calcium-binding site on metabotropic glutamate receptor 1{alpha}
(mGluR1{alpha}) that controls receptor activation, J. Biol. Chem. 285
(43) (2010) 33463–33474.
[68] C. Zhang, N. Mulpuri, F.M. Hannan, M.A. Nesbit, R.V. Thakker, D.
Hamelberg, E.M. Brown, J.J. Yang, Role of Ca2+ and L-Phe in regulating
functional cooperativity of disease-associated “toggle” calcium-sensing
receptor mutations, PLOS ONE 9 (11) (2014) e113622.
[69] C. Zhang, Y. Zhuo, H.A. Moniz, S. Wang, K.W. Moremen, J.H. Preste-
gard, E.M. Brown, J.J. Yang, Direct determination of multiple ligand
interactions with the extracellular domain of the calcium-sensing receptor,
J. Biol. Chem. 289 (48) (2014) 33529–33542.
[70] H.R. Toka, M.R. Pollak, P. Houillier, Calcium sensing in the renal tubule,
Physiology (Bethesda) 30 (4) (2015) 317–326.
[71] J.P. Pin, T. Galvez, L. Prezeau, Evolution, structure, and activation mech-
anism of family 3/C G-protein-coupled receptors, Pharmacol. Ther. 98
(3) (2003) 325–354.
[72] S.C. Brennan, A.D. Conigrave, Regulation of cellular signal transduc-
tion pathways by the extracellular calcium-sensing receptor, Curr. Pharm.
Biotechnol. 10 (3) (2009) 270–281.
[73] Y. Huang, J. Niwa, G. Sobue, G.E. Breitwieser, Calcium-sensing receptor
ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin,
J. Biol. Chem. 281 (17) (2006) 11610–11617.
[74] S. Lorenz, R. Frenzel, R. Paschke, G.E. Breitwieser, S.U. Miedlich,
Functional desensitization of the extracellular calcium-sensing recep-
tor is regulated via distinct mechanisms: role of G protein-coupled
d HumF. Pu et al. / Food Science an
receptor kinases, protein kinase C and beta-arrestins, Endocrinology 148
(5) (2007) 2398–2404.
[75] H. Awata, C. Huang, M.E. Handlogten, R.T. Miller, Interaction of the
calcium-sensing receptor and filamin, a potential scaffolding protein, J.
Biol. Chem. 276 (37) (2001) 34871–34879.
[76] S.Y. Jung, J.O. Kwak, H.W. Kim, D.S. Kim, S.D. Ryu, C.B. Ko, S.H.
Cha, Calcium sensing receptor forms complex with and is up-regulated
by caveolin-1 in cultured human osteosarcoma (Saos-2) cells, Exp. Mol.
Med. 37 (2) (2005) 91–100.
[77] I. Dal Pra, A. Chiarini, E.F. Nemeth, U. Armato, J.F. Whitfield, Roles of
Ca2+ and the Ca2+-sensing receptor (CASR) in the expression of inducible
NOS (nitric oxide synthase)-2 and its BH4 (tetrahydrobiopterin)-
dependent activation in cytokine-stimulated adult human astrocytes, J
Cell Biochem. 96 (2) (2005) 428–438.
[78] E.M. Brown, G. Gamba, D. Riccardi, M. Lombardi, R. Butters, O. Kifor,
A. Sun, M.A. Hediger, J. Lytton, S.C. Hebert, Cloning and characteriza-
tion of an extracellular Ca(2+)-sensing receptor from bovine parathyroid,
Nature 366 (6455) (1993) 575–580.
[79] E.M. Brown, R.J. MacLeod, Extracellular calcium sensing and extracel-
lular calcium signaling, Physiol. Rev. 81 (1) (2001) 239–297.
[80] A.M. Hofer, E.M. Brown, Extracellular calcium sensing and signalling,
Nat. Rev. Mol. Cell. Biol. 4 (7) (2003) 530–538.
[81] Y. Huang, Y. Zhou, A. Castiblanco, W. Yang, E.M. Brown, J.J.
Yang, Multiple Ca(2+)-binding sites in the extracellular domain of the
Ca(2+)-sensing receptor corresponding to cooperative Ca(2+) response,
Biochemistry 48 (2) (2009) 388–398.
[82] Y. Huang, Y. Zhou, W. Yang, R. Butters, H.W. Lee, S. Li, A. Castiblanco,
E.M. Brown, J.J. Yang, Identification and dissection of Ca(2+)-binding
sites in the extracellular domain of Ca(2+)-sensing receptor, J. Biol.
Chem. 282 (26) (2007) 19000–19010.
[83] E.M. Brown, Role of the calcium-sensing receptor in extracellular calcium
homeostasis, Best Pract. Res. Clin. Endocrinol. Metab. 27 (3) (2013)
333–343.
[84] T. Kameda, H. Mano, Y. Yamada, H. Takai, N. Amizuka, M. Kobori, N.
Izumi, H. Kawashima, H. Ozawa, K. Ikeda, A. Kameda, Y. Hakeda, M.
Kumegawa, Calcium-sensing receptor in mature osteoclasts, which are
bone resorbing cells, Biochem. Biophys. Res. Commun. 245 (2) (1998)
419–422.
[85] B. Chakravarti, N. Chattopadhyay, E.M. Brown, Signaling through the
extracellular calcium-sensing receptor (CaSR), Adv. Exp. Med. Biol. 740
(2012) 103–142.
[86] M. Freichel, A. Zink-Lorenz, A. Holloschi, M. Hafner, V. Flockerzi, F.
Raue, Expression of a calcium-sensing receptor in a human medullary
thyroid carcinoma cell line and its contribution to calcitonin secretion,
Endocrinology 137 (9) (1996) 3842–3848.
[87] J.P. Geibel, S.C. Hebert, The functions and roles of the extracellular Ca2+-
sensing receptor along the gastrointestinal tract, Annu. Rev. Physiol. 71
(2009) 205–217.
[88] S.W. Kooh, Rickets due to calcium deficiency, N. Engl. J. Med. (1977).
[89] B. Nordin, Osteoporosis and calcium deficiency, Proc. Nutr. Soc. 19 (02)
(1960) 129–137.
[90] J.A. Buckwalter, R.R. Cooper, Bone structure and function, Instr. Course.
Lect. 36 (1987) 27–48.
[91] M. Brini, D. Ottolini, T. Cali, E. Carafoli, Calcium in health and disease,
Met. Ions Life Sci. 13 (2013) 81–137.
[92] J.A. Beto, The role of calcium in human aging, Clin. Nutr. Res. 4 (1)
(2015) 1–8.
[93] C.C. Johnston Jr., J.Z. Miller, C.W. Slemenda, T.K. Reister, S. Hui,
J.C. Christian, M. Peacock, Calcium supplementation and increases in
bone mineral density in children, N. Engl. J. Med. 327 (2) (1992)
82–87.
[94] G. Carmeliet, V. Dermauw, R. Bouillon, Vitamin D signaling in cal-
cium and bone homeostasis: a delicate balance, Best Pract. Res. Clin.
Endocrinol. Metab. 29 (4) (2015) 621–631.[95] V. Vera, J.M. Moran, P. Barros, M.L. Canal-Macias, R. Guerrero-
Bonmatty, C. Costa-Fernandez, J.M. Lavado-Garcia, R. Roncero-Martin,
J.D. Pedrera-Zamorano, Greater calcium intake is associated with bet-
ter bone health measured by quantitative ultrasound of the phalanges inan Wellness 5 (2016) 8–16 15
pediatric patients treated with anticonvulsant drugs, Nutrients 7 (12)
(2015) 9908–9917.
[96] H. Gao, X. Wei, J. Liao, R. Wang, J. Xu, X. Liu, X. Pan, Z. Li, Z. Li, Y.
Xia, Q. Wang, Lower bone mineral density in patients with parkinson’s
disease: a cross-sectional study from Chinese Mainland, Front. Aging.
Neurosci. 7 (2015) 203.
[97] W. Cramer, On the biochemical mechanism of growth. The effect of
sodium and calcium ions on the growth of a transplantable mouse carci-
noma, Biochem. J. 12 (3) (1918) 210–220.
[98] J. Wactawski-Wende, J.M. Kotchen, G.L. Anderson, A.R. Assaf, R.L.
Brunner, M.J. O’Sullivan, K.L. Margolis, J.K. Ockene, L. Phillips, L.
Pottern, R.L. Prentice, J. Robbins, T.E. Rohan, G.E. Sarto, S. Sharma,
M.L. Stefanick, L. Van Horn, R.B. Wallace, E. Whitlock, T. Bassford,
S.A. Beresford, H.R. Black, D.E. Bonds, R.G. Brzyski, B. Caan, R.T.
Chlebowski, B. Cochrane, C. Garland, M. Gass, J. Hays, G. Heiss, S.L.
Hendrix, B.V. Howard, J. Hsia, F.A. Hubbell, R.D. Jackson, K.C. John-
son, H. Judd, C.L. Kooperberg, L.H. Kuller, A.Z. LaCroix, D.S. Lane,
R.D. Langer, N.L. Lasser, C.E. Lewis, M.C. Limacher, J.E. Manson,
I. Women’s Health Initiative, Calcium plus vitamin D supplementation
and the risk of colorectal cancer, N. Engl. J. Med. 354 (7) (2006)
684–696.
[99] K. Uusi-Rasi, M.U. Karkkainen, C.J. Lamberg-Allardt, Calcium intake
in health maintenance – a systematic review, Food. Nutr. Res. 57 (2013).
[100] L. Fan, K. Strasser-Weippl, J.J. Li, J. St Louis, D.M. Finkelstein, K.D.
Yu, W.Q. Chen, Z.M. Shao, P.E. Goss, Breast cancer in China, Lancet
Oncol. 15 (7) (2014) e279–e289.
[101] F. Pu, S. Xue, J. Qiao, A. Patel, J.J. Yang, Towards the molecular imaging
of prostate cancer biomarkers using protein-based MRI contrast agents,
Curr. Protein Pept. Sci. (2016).
[102] F. Pu, J. Qiao, S. Xue, H. Yang, A. Patel, L. Wei, K. Hekmatyar, M.
Salarian, H.E. Grossniklaus, Z.R. Liu, J.J. Yang, GRPR-targeted protein
contrast agents for molecular imaging of receptor expression in cancers
by MRI, Sci. Rep. 5 (2015) 16214.
[103] S. Xue, J. Qiao, J. Jiang, K. Hubbard, N. White, L. Wei, S. Li, Z.R. Liu,
J.J. Yang, Design of ProCAs (protein-based Gd(3+) MRI contrast agents)
with high dose efficiency and capability for molecular imaging of cancer
biomarkers, Med. Res. Rev. 34 (5) (2014) 1070–1099.
[104] S. Li, J. Jiang, J. Zou, J. Qiao, S. Xue, L. Wei, R. Long, L.
Wang, A. Castiblanco, N. White, J. Ngo, H. Mao, Z.R. Liu, J.J.
Yang, PEGylation of protein-based MRI contrast agents improves
relaxivities and biocompatibilities, J. Inorg. Biochem. 107 (1) (2012)
111–118.
[105] J. Qiao, S. Xue, F. Pu, N. White, J. Jiang, Z.R. Liu, J.J. Yang, Molecu-
lar imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast
agents, J. Biol. Inorg. Chem. 19 (2) (2014) 259–270.
[106] S. Xue, J. Qiao, F. Pu, M. Cameron, J.J. Yang, Design of a novel class of
protein-based magnetic resonance imaging contrast agents for the molec-
ular imaging of cancer biomarkers, Wiley Interdiscip. Rev. Nanomed.
Nanobiotechnol. 5 (2) (2013) 163–179.
[107] Y. Cui, T.E. Rohan, Vitamin D, calcium, and breast cancer risk: a review,
Cancer Epidemiol. Biomark. Prev. 15 (8) (2006) 1427–1437.
[108] M. Iqbal, T.A. Khan, S.A. Maqbool, Vitamin D receptor Cdx-2 poly-
morphism and premenopausal breast cancer risk in southern Pakistani
patients, PLOS ONE 10 (3) (2015) e0122657.
[109] X. Li, X. Kong, L. Jiang, T. Ma, S. Yan, C. Yuan, Q. Yang, A genetic
polymorphism (rs17251221) in the calcium-sensing receptor is associated
with breast cancer susceptibility and prognosis, Cell Physiol. Biochem.
33 (1) (2014) 165–172.
[110] K.A. Bolanz, M.A. Hediger, C.P. Landowski, The role of TRPV6 in breast
carcinogenesis, Mol. Cancer. Ther. 7 (2) (2008) 271–279.
[111] I. Dhennin-Duthille, M. Gautier, M. Faouzi, A. Guilbert, M. Brevet, D.
Vaudry, A. Ahidouch, H. Sevestre, H. Ouadid-Ahidouch, High expression
of transient receptor potential channels in human breast cancer epithelial
cells and tissues: correlation with pathological parameters, Cell Physiol.
Biochem. 28 (5) (2011) 813–822.
[112] A.I. Fleischman, H. Yacowitz, T. Hayton, M.L. Bierenbaum, Effects of
dietary calcium upon lipid metabolism in mature male rats fed beef tallow,
J. Nutr. 88 (3) (1966) 255–260.
1 d Hum6 F. Pu et al. / Food Science an
[113] H. Yacowitz, A.I. Fleischman, M.L. Bierenbaum, D. Kritchevsky, Cal-
cium and lipid metabolism: effects of increased dietary calcium on
atherosclerosis in rabbits, Trans. N. Y. Acad. Sci. 33 (3) (1971) 344–350.
[114] S. Rautiainen, L. Wang, J.E. Manson, H.D. Sesso, The role of calcium
in the prevention of cardiovascular disease – a review of observational
studies and randomized clinical trials, Curr. Atheroscler. Rep. 15 (11)
(2013) 362.
[115] L.M. Resnick, J.H. Laragh, J.E. Sealey, M.H. Alderman, Divalent cations
in essential hypertension. Relations between serum ionized calcium, mag-
nesium, and plasma renin activity, N. Engl. J. Med. 309 (15) (1983)
888–891.
[116] C.S. Shin, K.M. Kim, The risks and benefits of calcium supplementation,
Endocrinol. Metab. (Seoul). 30 (1) (2015) 27–34.an Wellness 5 (2016) 8–16
[117] S. Schrager, Dietary calcium intake and obesity, J. Am. Board Fam. Pract.
18 (3) (2005) 205–210.
[118] M.J. Bolland, A. Grey, I.R. Reid, Calcium supplements and cardiovascu-
lar risk: 5 years on, Ther. Adv. Drug. Saf. 4 (5) (2013) 199–210.
[119] I.R. Reid, Cardiovascular effects of calcium supplements, Nutrients 5 (7)
(2013) 2522–2529.
[120] M. Tseng, R.A. Breslow, B.I. Graubard, R.G. Ziegler, Dairy, calcium,
and vitamin D intakes and prostate cancer risk in the National Health
and Nutrition Examination Epidemiologic Follow-up Study cohort, Am.
J. Clin. Nutr. 81 (5) (2005) 1147–1154.
[121] E. Giovannucci, Y. Liu, M.J. Stampfer, W.C. Willett, A prospective study
of calcium intake and incident and fatal prostate cancer, Cancer Epi-
demiol. Biomark. Prev. 15 (2) (2006) 203–210.
